Aktis Oncology, Inc. (AKTS)
NASDAQ: AKTS · Real-Time Price · USD
19.06
+0.25 (1.33%)
At close: Mar 9, 2026, 4:00 PM EDT
19.07
+0.01 (0.05%)
After-hours: Mar 9, 2026, 5:00 PM EDT
Aktis Oncology Revenue
Aktis Oncology had revenue of $933.00K in the quarter ending December 31, 2024. This brings the company's revenue in the last twelve months to $5.56M. In the year 2024, Aktis Oncology had annual revenue of $1.49M.
Revenue (ttm)
$5.56M
Revenue Growth
n/a
P/S Ratio
180.99
Revenue / Employee
$73,158
Employees
76
Market Cap
1.00B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.49M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionAKTS News
- 13 days ago - Aktis Oncology to Present at Upcoming March Investor Conferences - GlobeNewsWire
- 13 days ago - Aktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein Radioconjugate - GlobeNewsWire
- 7 weeks ago - Aktis Oncology Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 2 months ago - U.S. IPO Weekly Recap: Aktis Oncology Leads As First Sizable 2026 IPO - Seeking Alpha
- 2 months ago - Vida Ventures Congratulates Aktis Oncology on Its Entry into the Public Markets - Business Wire
- 2 months ago - Aktis Oncology prices upsized US IPO at $18 per share - Reuters
- 2 months ago - Aktis Oncology Announces Pricing of its Upsized Initial Public Offering - GlobeNewsWire
- 2 months ago - Aktis Oncology Pursues $200 Million IPO On Promising Early Stage Studies - Seeking Alpha